TransMedics is building a defensible warm-perfusion and logistics platform with substantial kidney-driven upside, but near-term margin compression, dilution, and execution risk make the asymmetric valuation highly scenario-dependent.
Overview
TransMedics is a commercial-stage medtech company attempting to make warm normothermic perfusion the standard for solid-organ transplantation. Its OCS Heart, Lung, and Liver systems combine reusable consoles with organ-specific disposable sets, while the National OCS Program adds clinical specialists, screening, and vertically integrated air and ground logistics. This ecosystem addresses the limitations of static cold storage by extending transport times, assessing organ function, and enabling use of organs that might otherwise be discarded. **Q2 2026 revenue reached a record $189.9 million, up 20.7% year over year and 9.2% sequentially**, led by liver revenue of $148.0 million and service revenue growth of 28.5%. However, profitability weakened: gross margin fell to 59.6%, GAAP net income declined 55% to $14.7 million, and adjusted operating-margin guidance fell to 12.5%-14.0% as R&D and infrastructure spending accelerated. Management raised 2026 revenue guidance to $737 million-$757 million. The key catalyst is OCS Kidney, with first clinical experience targeted for 2027, alongside European expansion through PAD Aviation. At $88.30, valuation is approximately 4.1x TTM sales and 23.0x trailing P/E, leaving considerable upside if the kidney thesis works but severe downside if execution falters.